newsfilter
← Latest News
GlobeNewswire·

Selecta Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update

– DISSOLVE I & II studies of SEL-212 in Chronic Refractory Gout remain on track for joint topline data readout in Q1 2023 – – SEL-302, Selecta's wholly owned gene therapy in combination with ImmTOR for the